|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0004083,
umls-concept:C0018017,
umls-concept:C0021735,
umls-concept:C0025202,
umls-concept:C0027651,
umls-concept:C0205147,
umls-concept:C0205263,
umls-concept:C0332448,
umls-concept:C0456599,
umls-concept:C0600558,
umls-concept:C1167395,
umls-concept:C1571702,
umls-concept:C1709059,
umls-concept:C1718423,
umls-concept:C1817908
|
|
pubmed:issue |
19
|
|
pubmed:dateCreated |
2006-6-30
|
|
pubmed:abstractText |
Adjuvant high-dose interferon-alfa-2b (HDI) improves disease-free and overall survival in patients with high-risk melanoma. However, its mechanism of action is largely unknown. Therefore, HDI was investigated in the neoadjuvant setting to assess clinical and pathologic responses after 4 weeks of HDI and to perform immunohistochemical evaluation of immune cell subsets and melanoma-associated antigens.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3164-71
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16809739-Adult,
pubmed-meshheading:16809739-Aged,
pubmed-meshheading:16809739-Antigens, CD,
pubmed-meshheading:16809739-Antineoplastic Agents,
pubmed-meshheading:16809739-Female,
pubmed-meshheading:16809739-Humans,
pubmed-meshheading:16809739-Interferon-alpha,
pubmed-meshheading:16809739-Lymph Node Excision,
pubmed-meshheading:16809739-Lymphocyte Subsets,
pubmed-meshheading:16809739-Male,
pubmed-meshheading:16809739-Melanoma,
pubmed-meshheading:16809739-Middle Aged,
pubmed-meshheading:16809739-Neoadjuvant Therapy,
pubmed-meshheading:16809739-Recombinant Proteins,
pubmed-meshheading:16809739-Skin Neoplasms,
pubmed-meshheading:16809739-Survival Analysis,
pubmed-meshheading:16809739-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.
|
|
pubmed:affiliation |
Melanoma and Skin Cancer Program, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
